Go to the Content   Sunday, 19 May 2013

Close

About cookies: we use cookies to support features like login and sharing articles. Keep cookies enabled to enjoy the full site experience. By browsing our site with cookies enabled, you are agreeing to their use. Review our cookies information for more details.
 

Taming tiny technology, before it bites back

By Eliza Gray  -  06.03.2008 / 00:00 CET
Nanotechnology needs to be handled with care by EU regulators if its potential is to be fulfilled.
 

This article is reserved for paying subscribers...

FullOffer_small

Log-in:

Password:

Forgot your password? Just type in your email address and click on the Log In button

Select your offer today and receive:

Register Online Print
Hover over for more info

Free

€3 per week

€3.50 per week

Daily online news
Full access on mobile devices
E-alert customisable by policy
Access to editorial, comment
Profiles
Special reports
Access to the archives
Access to the e-paper
Newspaper delivered weekly
Register
Select offer
Select offer

For more information please contact evsubscriptions@economist.com or call +32 2 540 9098


Please log in to read this article:

Log-in

Password

Forgot your password? Just type in your e-mail address and click on the Log In button

 

Don't have a login yet?

Discover your benefits and register for free now! It only takes a minute.

Register for free

© 2013 European Voice. All rights reserved.
Varrow

Most viewed in Special reports

Related articles

ALLOWING the US to export 30,000 tonnes of poultry meat to the EU, 0.3% of its total consumption, may not seem much of a breakthrough in a transatlantic trade relationship worth €1.6 trillion. But if, as expected, in June the EU ends the ban it has maintained for 11 years because the US uses antimicrobial agents to eliminate salmonella, it will mark the first positive result of the Transatlantic Economic Council.

Negotiations over Economic Partnership Agreements (EPA) with the European Commission have divided the African, Caribbean and Pacific countries that are the ostensible beneficiaries. The Commission has managed to secure the initialling of some agreements, but the majority of ACP states have refused to take such a step.

Policymakers are finding it hard to explain a potential health risk to citizens.

Robert Madelin talks about DG Sanco's plans.

The Lisbon treaty marks a change from a directive-based approach to health to a preventative one.

Advertisement

Comments

 

Your comment
Please note: The fields followed by an asterisk (*) are obligatory fields

Comment*

Name*
E-mail*
Website
 I accept the Terms & conditions
 I would like to share my e-mail & website

Advertisement

Cookies info | Privacy policy | Terms & conditions